Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's DiseaseGlobeNewsWire • 10/26/25
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the KeyZacks Investment Research • 10/24/25
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology PortfolioGlobeNewsWire • 10/24/25
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/23/25
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025GlobeNewsWire • 10/22/25
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes TurnaroundThe Motley Fool • 10/20/25
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”GlobeNewsWire • 10/13/25
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?Zacks Investment Research • 10/10/25
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeGlobeNewsWire • 10/09/25
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeBusiness Wire • 10/09/25
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's DiseasePRNewsWire • 10/06/25
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in ChinaGlobeNewsWire • 09/28/25
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/24/25
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in AustraliaGlobeNewsWire • 09/24/25